Homocysteine and cardiovascular disease: Current evidence and future prospects

被引：171

作者：

Mangoni, AA ^{[1
]}

Jackson, SHD ^{[1
]}

机构：

[1] Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Hlth Care Elderly, London WC2R 2LS, England

来源：

AMERICAN JOURNAL OF MEDICINE | 2002年 / 112卷 / 07期

关键词：

D O I：

10.1016/S0002-9343(02)01021-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hyperhomocysteinemia is an independent risk factor for cardiovascular disease, Despite the well-known effectiveness of vitamin supplementation in reducing homocysteine levels, it is not known whether lowering of homocysteine levels is associated with a reduction in cardiovascular morbidity and mortality. The aim of this review is to discuss the epidemiologic evidence about the relation between homocysteine and cardiovascular disease, the pathophysiologic mechanisms responsible for the deleterious vascular and hemostatic effects of homocysteine, and studies of the potential benefits of homocysteine-lowering therapy.

引用

收藏

页码：556 / 565

页数：10

相关论文

共 99 条

[81] Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria [J].

Stehouwer, CDA ;

Gall, MA ;

Hougaard, P ;

Jakobs, C ;

Parving, HH .

KIDNEY INTERNATIONAL, 1999, 55 (01) :308-314

[82] Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men - A 10-year follow-up [J].

Stehouwer, CDA ;

Weijenberg, MP ;

van den Berg, M ;

Jakobs, C ;

Feskens, EJM ;

Kromhout, D .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (12) :1895-1901

[83] Effect of homocysteine on carotid intima-media thickness after renal transplantation [J].

Suwelack, B ;

Gerhardt, U ;

Witta, J ;

Rahn, KH ;

Hohage, H .

CLINICAL TRANSPLANTATION, 2000, 14 (06) :555-560

[84]

Thambyrajah J, 2000, CIRCULATION, V102, P871, DOI 10.1161/01.CIR.102.8.871

[85] Homozygosity for the C677 → T mutation of 5,10-methylenetetrahydrofolate reductase and total plasma homocyst(e)ine are not associated with greater than normal risk of a first myocardial infarction in northern Sweden [J].

Thögersen, AM ;

Nilsson, TK ;

Dahlen, G ;

Jansson, JH ;

Boman, K ;

Huhtasaari, F ;

Hallmans, G .

CORONARY ARTERY DISEASE, 2001, 12 (02) :85-90

[86] Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives [J].

Tonstad, S ;

Refsum, H ;

Sivertsen, M ;

Christophersen, B ;

Ose, L ;

Ueland, PM .

PEDIATRIC RESEARCH, 1996, 40 (01) :47-52

[87] PROMOTION OF VASCULAR SMOOTH-MUSCLE CELL-GROWTH BY HOMOCYSTEINE - A LINK TO ATHEROSCLEROSIS [J].

TSAI, JC ;

PERRELLA, MA ;

YOSHIZUMI, M ;

HSIEH, CM ;

HABER, E ;

SCHLEGEL, R ;

LEE, ME .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) :6369-6373

[88]

UELAND PM, 1993, CLIN CHEM, V39, P1764

[89] Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation [J].

Undas, A ;

Domagala, TB ;

Jankowski, M ;

Szczeklik, A .

THROMBOSIS RESEARCH, 1999, 95 (06) :281-288

[90] Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase [J].

Upchurch, GR ;

Welch, GN ;

Fabian, AJ ;

Freedman, JE ;

Johnson, JL ;

Keaney, JF ;

Loscalzo, J .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (27) :17012-17017

← 1 2 3 4 5 6 7 8 9 10 →